Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Income towards Parent Company (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Income towards Parent Company for 12 consecutive years, with -$23.3 million as the latest value for Q1 2026.

  • For Q1 2026, Income towards Parent Company fell 53.7% year-over-year to -$23.3 million; the TTM value through Mar 2026 reached -$160.1 million, down 314.59%, while the annual FY2025 figure was -$153.9 million, 293.67% down from the prior year.
  • Income towards Parent Company hit -$23.3 million in Q1 2026 for Crescent Biopharma, up from -$90.4 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$2.6 million in Q3 2024 and bottomed at -$90.4 million in Q4 2025.
  • Average Income towards Parent Company over 5 years is -$17.6 million, with a median of -$10.5 million recorded in 2023.
  • Year-over-year, Income towards Parent Company surged 71.41% in 2024 and then tumbled 835.27% in 2025.
  • Crescent Biopharma's Income towards Parent Company stood at -$10.2 million in 2022, then rose by 11.38% to -$9.1 million in 2023, then soared by 71.02% to -$2.6 million in 2024, then plummeted by 3335.84% to -$90.4 million in 2025, then skyrocketed by 74.24% to -$23.3 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at -$23.3 million, -$90.4 million, and -$24.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.